Epidemiology of AIDS dementia complex in Europe

被引:91
作者
Chiesi, A
Vella, S
Dally, LG
Pedersen, C
Danner, S
Johnson, AM
Schwander, S
Goebel, FD
Glauser, M
Antunes, F
Lundgren, JD
机构
[1] ACAD MED CTR,AMSTERDAM,NETHERLANDS
[2] HVIDOVRE UNIV HOSP,COPENHAGEN,DENMARK
[3] UCL,SCH MED,LONDON,ENGLAND
[4] BERNHARD NOCHT INST TROP MED,HAMBURG,GERMANY
[5] UNIV MUNICH,MED POLIKLIN,W-8000 MUNICH,GERMANY
[6] CHU VAUDOIS,CH-1011 LAUSANNE,SWITZERLAND
[7] HOSP SANTA MARIA,LISBON,PORTUGAL
来源
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY | 1996年 / 11卷 / 01期
关键词
AIDS dementia complex; epidemiology in Europe; zidovudine; prophylaxis;
D O I
10.1097/00042560-199601010-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The aim of the study was to describe the epidemiology of AIDS dementia complex (ADC) in Europe and to assess the possible role of zidovudine therapy in preventing or delaying its occurrence. We used an inception cohort, with data collected retrospectively from patients' clinical records from 52 clinical centers in 17 countries across Europe. The subjects were 6,548 adult people with AIDS consecutively diagnosed from 1979 to 1989. The main outcome measures were codiagnosis of ADC at the time of AIDS diagnosis and ADC-free time after AIDS diagnosis. ADC was reported in 295 patients (4.5%) at the time of AIDS diagnosis and during follow-up in a further 402 of the 5,160 patients (7.8%) who were diagnosed with AIDS based on diseases other than ADC. Whether at the time of AIDS diagnosis or later, the occurrence of ADC was significantly associated with age, transmission category, and CD4(+) cell counts. The risk was greater in older patients (14 and 19% greater, at AIDS diagnosis and after, respectively, for a 5-year difference in age), in i.v. drug users than in homosexual and bisexual men (89 and 60% greater, at AIDS diagnosis and after, respectively), and for people with lower CD4(+) cell counts (14 and 30% greater for a reduction of 1 on the natural log scale). Risk was almost double for women than for men. A significant reduction, of similar to 40%, was found in the risk of developing ADC after AIDS diagnosis for patients receiving zidovudine therapy, but this effect was present only during the first 18 months of treatment, irrespective of whether treatment began before or after AIDS diagnosis. In conclusion, an increase in the risk of developing ADC either at the time of AIDS diagnosis or thereafter is associated with increasing age, i.v. drug use, and decreased CD4(+) cell count. Women tend to have a higher risk of ADC at the time of AIDS diagnosis. Zidovudine therapy appears to have a definite, but time-limited, effect of protecting patients against ADC development after AIDS diagnosis.
引用
收藏
页码:39 / 44
页数:6
相关论文
共 20 条
[1]  
[Anonymous], 1991, NEUROLOGY, V41, P778
[2]  
CHIESI A, 1992, 3 EUR C CLIN ASP TRE
[3]  
CHIESI A, 1993, 9TH INT C AIDS BERL
[4]   ZIDOVUDINE REDUCES INTRATHECAL IMMUNOACTIVATION IN PATIENTS WITH EARLY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
ELOVAARA, I ;
POUTIAINEN, E ;
LAHDEVIRTA, J ;
HOKKANEN, L ;
RAININKO, R ;
MATTINEN, S ;
VIRTA, A ;
SUNI, J ;
RANKI, A .
ARCHIVES OF NEUROLOGY, 1994, 51 (09) :943-950
[5]   ZIDOVUDINE THERAPY AND HIV ENCEPHALITIS - A 10-YEAR NEUROPATHOLOGICAL SURVEY [J].
GRAY, F ;
BELEC, L ;
KEOHANE, C ;
DETRUCHIS, P ;
CLAIR, B ;
DURIGON, M ;
SOBEL, A ;
GHERARDI, R .
AIDS, 1994, 8 (04) :489-493
[6]   THE SPECTRUM OF HIV-1-RELATED DISEASE AMONG OUTPATIENTS IN NEW-YORK-CITY [J].
GREENBERG, AE ;
THOMAS, PA ;
LANDESMAN, SH ;
MILDVAN, D ;
SEIDLIN, M ;
FRIEDLAND, GH ;
HOLZMAN, R ;
STARRETT, B ;
BRAUN, J ;
BRYAN, EL ;
EVANS, RF .
AIDS, 1992, 6 (08) :849-859
[7]   EPIDEMIOLOGY OF HUMAN-IMMUNODEFICIENCY-VIRUS ENCEPHALOPATHY IN THE UNITED-STATES [J].
JANSSEN, RS ;
NWANYANWU, OC ;
SELIK, RM ;
STEHRGREEN, JK .
NEUROLOGY, 1992, 42 (08) :1472-1476
[8]  
LEVY RM, 1988, AIDS NERVOUS SYSTEM, P29
[9]  
LEVY RM, 1988, AIDS NERVOUS SYSTEM, P13
[10]   COMPARISON OF LONG-TERM PROGNOSIS OF PATIENTS WITH AIDS TREATED AND NOT TREATED WITH ZIDOVUDINE [J].
LUNDGREN, JD ;
PHILLIPS, AN ;
PEDERSEN, C ;
CLUMECK, N ;
GATELL, JM ;
JOHNSON, AM ;
LEDERGERBER, B ;
VELLA, S ;
NIELSEN, JO ;
DEWIT, S ;
SOMMEREIJNS, B ;
NIELSEN, T ;
JENSEN, G ;
SKINHOJ, P ;
BENTSEN, K ;
GERSTOFT, J ;
MELBYE, M ;
RANKI, A ;
VALLE, SL ;
KATLAMA, C ;
BERLUREAU, P ;
DIETRICH, M ;
SCHWANDER, S ;
GOEBEL, FD ;
KOSMIDIS, J ;
STERGIOU, G ;
GOUZIA, T ;
PAPADOPOULOS, A ;
BANHEGYI, D ;
MULCAHY, F ;
YUST, I ;
BENISHAI, Z ;
BENTWICH, Z ;
SACKS, T ;
MAAYAN, S ;
CHIESI, A ;
ANCARANI, F ;
SCALISE, G ;
BERTAGGIA, A ;
FRANCAVILLA, E ;
CALONGHI, G ;
CARGNEL, A ;
ARLOTTI, M ;
CIAMMARUGHI, R ;
COLOMBA, A ;
DELALLA, F ;
FASSIO, P ;
FERLINI, A ;
FIACCADORI, F ;
PASETTI, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (14) :1088-1092